20/20 Biolabs Inc (NASDAQ:AIDX – Get Free Report) shares were up 3.5% during trading on Friday . The stock traded as high as $1.85 and last traded at $1.78. Approximately 96,513 shares traded hands during trading, a decline of 70% from the average daily volume of 322,076 shares. The stock had previously closed at $1.72.
Analysts Set New Price Targets
Separately, Wall Street Zen raised 20/20 Biolabs to a “hold” rating in a report on Saturday, March 14th.
Get Our Latest Stock Report on 20/20 Biolabs
20/20 Biolabs Stock Performance
About 20/20 Biolabs
We develop and commercialize AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. We offer two families of lab tests, both under our OneTest brand: (i) OneTest for Cancer, a multi-cancer early detection, or MCED, blood test which has been our primary commercial focus and source of revenues since we wound down our COVID-19 testing business, and (ii) OneTest for Longevity, which measures inflammatory biomarkers, that we expect to launch in the first half of 2026.
Recommended Stories
Receive News & Ratings for 20/20 Biolabs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 20/20 Biolabs and related companies with MarketBeat.com's FREE daily email newsletter.
